ISSN:
1420-908X
Keywords:
Tebufelone
;
NE-11740
;
NSAID
;
Arachidonate metabolism
;
Cyclooxygenase
;
5-Lipoxygenase
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Tebufelone is a novel nonsteroidal anti-inflammatory drug (NSAID), of the di-tert-butylphenol (DTBP) class, which displays potent anti-inflammatory, analgesic and anti-pyretic properties in a variety of animal models. In this report, the effects of Tebufelone on arachidonic acid (AA) metabolism are reviewed. Tebufelone potently inhibits the formation of prostaglandins (PGE2) a key mediator of pain and inflammation, in isolated enzyme preparations (IC50=1.5 μM,K I=0.35 μM), twoin vitro cellular systems: rat peritoneal macrophages (IC50=0.02 μM) and human whole blood (IC50=0.08 μM), andex vivo in man. In addition to PGE2 inhibition, which is common to all NSAIDs, higher concentrations of Tebufelone block thein vitro formation of products of the lipoxygenase pathway [leukotrienes (LTB4)] in rat macrophages (IC50=20 μM) and human whole blood (IC50=22 μM). Substrate incorporation studies (14C-AA) indicate that Tebufelone reversibly inhibits cyclooxygenase (CO) and 5-lipoxygenase (5-LO) enzymes rather than regulating the release of AA. Tebufelone was shown to be a more potent CO inhibitor than indomethacin and a less potent 5-LO inhibitor than RG-5901. Comparisons to structurally related compounds under development (E-5110, Esai; KME-4, Kanagafuchi), found Tebufelone to be the most potent CO inhibitorin vitro. All three DTBP compounds were equipotent 5-LO inhibitors. It is likely that Tebufelone's inhibitory effects on AA metabolism are, in part, responsible for itsin vivo efficacy and enhanced safety profile.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02001910
Permalink